Singapore Markets closed
Straits Times Index
3,269.27 -32.69 (-0.99%) Nikkei
28,546.98 +727.65 (+2.62%) Hang Seng
20,175.62 +93.19 (+0.46%) FTSE 100
7,500.89 +34.98 (+0.47%) BTC-USD
24,537.65 -200.57 (-0.81%) CMC Crypto 200
574.64 +3.36 (+0.59%)
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 623.90 |
| Open | 628.87 |
| Bid | 619.00 x 1200 |
| Ask | 630.50 x 3000 |
| Day's range | 622.30 - 632.37 |
| 52-week range | 538.01 - 747.42 |
| Volume | |
| Avg. volume | 653,735 |
| Market cap | 67.613B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 10.06 |
| EPS (TTM) | 62.53 |
| Earnings date | 03 Feb 2022 - 07 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 685.14 |
- Motley Fool
If You Invested $10,000 in Regeneron Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today
Regeneron Pharmaceuticals (NASDAQ: REGN) has been a reliable, steadily growing stock over the years, with the top line and profits increasing. Below, I'll look at just how well the stock has performed over the past five years and whether Regeneron is a good buy moving forward. In early August 2017, shares of Regeneron were trading at around $470 per share.
- Zacks
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
© 2022 Yahoo. All rights reserved.
